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Background: Excess bodyweight and related metabolic perturbations have been implicated 
in kidney cancer aetiology, but the specific molecular mechanisms underlying these 
relationships are poorly understood. In this study we sought to identify circulating 
metabolites that predispose kidney cancer and to evaluate the extent to which they are 
influenced by body-mass index (BMI).  
Methods and Findings: We assessed the association between circulating levels of 1,416 
metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 
kidney cancer case-control pairs from five prospective cohort studies. Cases were diagnosed 
on average eight years after blood collection. We found 25 metabolites robustly associated 
with kidney cancer risk. In particular, 14 glycerophospholipids (GPL) were inversely 
associated with risk, including eight phosphatidylcholines (PC) and two plasmalogens. The 
PC with the strongest association was PC ae C34:3 with an odds-ratio (OR) for one standard 
deviation (SD) increment of 0.75 (95% CI: 0.68 to 0.83, p=2.6x10-8). In contrast, four amino 
acids, including glutamate (OR for 1 SD=1.39, 95% CI: 1.20 - 1.60, p=1.6x10-5), were 
positively associated with risk. Adjusting for BMI partly attenuated the risk association for 
some – but not all – metabolites, whereas other known risk factors of kidney cancer, such as 
smoking and alcohol consumption, had minimal impact on the observed associations. A 
Mendelian randomization analysis of the influence of BMI on the blood metabolome 
highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. 
Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found 
inversely associated with kidney cancer risk (e.g -0.17 standard deviation change [ßBMI] in 1-
(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p=3.4x10-5). 




Whilst our results were robust across the participating studies, they were limited to study 
participants of European descent and it will, therefore, be important to evaluate if our 
findings can be generalized to populations with different genetic backgrounds. 
Conclusions: This study suggests a potentially important role of the blood metabolome in 
kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk 
of developing kidney cancer, and the extent to which changes in levels of these metabolites 
are driven by BMI - the principal modifiable risk factor of kidney cancer. 
 
Author summary 
Why was this study done? 
• Several modifiable risk factors have been established for kidney cancer, amongst 
which elevated BMI and obesity are central. 
• The biological mechanisms underlying these relationships are poorly understood, but 
obesity-related metabolic perturbations may be important. 
What did the researchers do and find? 
• We looked at the association between kidney cancer and the levels of 1,416 
metabolites measured in blood on average eight years before the disease onset. The 
study included 1,305 kidney cancer cases and 1,305 healthy controls.  
• We found 25 metabolites robustly associated with kidney cancer risk.   
• Specifically, multiple glycerophospholipids were inversely associated with risk, while 
several amino acids were positively associated with risk.  
• Accounting for body-mass index (BMI) highlighted that some – but not all – 




What do these findings mean? 
• These findings illustrate the potential utility of prospectively measured metabolites 
in helping us to understand the aetiology of kidney cancer. 
• By examining overlap between the metabolomic profile of prospective risk of kidney 
cancer and that of modifiable risk factors for the disease – in this case BMI – we can 






Kidney cancer is the 14th most common cancer worldwide with renal cell carcinoma (RCC) 
making up the majority of cases[1]. There are important geographical variations in kidney 
cancer incidence that are only partly understood [2]. Excess bodyweight and related 
conditions, such as hypertension, diabetes, and related metabolic perturbations, are among 
the most robustly implicated risk factors for kidney cancer, with support from both traditional 
observational studies and genetic studies [2-7].  For instance, in the UK, an estimated 24% of 
kidney cancer cases are attributable to overweight and obesity, making this the leading 
modifiable risk factor for the disease [8]. Germline mutations responsible for an inherited 
predisposition to kidney cancer (a small proportion of kidney cancer cases) have a key role in 
regulating cellular metabolism [9] and this, together with evidence of extensive metabolic 
reprogramming within tumours themselves [10], have led to the characterisation of kidney 
cancer as a metabolic disease. However, the molecular mechanisms predisposing kidney 
cancer remain largely unknown. Given the likely metabolic underpinnings of kidney cancer, 
studies of circulating metabolites, the downstream products of cellular regulatory processes, 
may improve our understanding into pathways relevant to kidney cancer aetiology [11]. 
Metabolite variations are the result of genetic and non-genetic factors and provide a read-
out of physiological functions [12]. Metabolomics technologies based on mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) have enabled the systematic quantification of 
hundreds of metabolites (the ‘metabolome’) from a single biological sample. The analysis of 
metabolites has enabled a more thorough exploration of an individual’s metabolic status, 
providing important insights into the biological pathways leading to diseases such as cancer 
[11,13,14] and has enabled the discovery and development of new drug targets[15]. Already, 




used to characterise kidney cancer and identify novel potential diagnostic biomarkers. 
However, because of the cross-sectional or retrospective design of these studies, they could 
not inform the identification of biomarkers for incident disease development. Prospective 
cohort studies, where healthy individuals initially donate blood at recruitment and are 
longitudinally followed over time for incident disease, can circumvent many of the problems 
of retrospective study designs - particularly where the focus is on identifying risk factors for 
disease onset.  
The aim of this study was to identify circulating metabolites associated with the development 
of kidney cancer in a prospective case-control framework. We used two complementary 
metabolomics platforms [28] to quantify over 1000 metabolites in blood samples donated by 
research participants later diagnosed with kidney cancer along with matched control subjects. 
In a series of follow-up analyses, including a two-sample Mendelian randomization (MR) 
analysis, which uses genetic variants as proxies for an exposure of interest [29], we evaluated 
the extent to which the metabolomic signature of disease risk could be explained by body 
mass index (BMI), the leading modifiable risk factor for kidney cancer.  
 
Methods 
Analytical strategy (Figure 1) 
The primary analysis was pre-defined and involved investigating the association between 
circulating levels of metabolites and kidney cancer risk using pre-diagnostic metabolomics 
measurements in a case-control study nested within multiple large-scale prospective cohorts 
(the MetKid consortium). Adjustment for known risk factors for kidney cancer (BMI, 




extent to which these could explain the associations between blood metabolites and kidney 
cancer risk. 
A natural complementary analysis would have been to interrogate the potentially causal role 
for the identified risk-associated metabolites in kidney cancer aetiology through Mendelian 
randomization (MR) analyses. However, given the methodological constraints of MR in this 
context, specifically, widespread pleiotropic instruments, which would violate the MR 
assumptions, we chose not to pursue this analysis. Our analysis plan was therefore revised, 
and as a secondary analysis, we rather used a two-sample MR approach to estimate the causal 
effect of BMI on the blood metabolome. This analysis complemented the main risk analysis 
by quantifying the extent to which BMI – the central risk factor of kidney cancer – influenced 
the identified risk metabolites. This study is reported as per the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) and STROBE-MR guidelines 
(Supplementary Tables S1 and S2) [30,31].   
Study population, sample collection and follow-up 
Our study population consisted of kidney cancer nested case-control studies drawn from 5 
independent cohorts: the European Prospective Investigation into Cancer and Nutrition 
(EPIC), The Melbourne Collaborative Cohort Study (MCCS), Northern Sweden Health and 
Disease study (NSHDS), University of Tartu - Estonian Biobank (Estonian BB) and The 
Trøndelag Health Study (HUNT) (Supplementary Table S3; details of the cohorts are described 
in the Supplementary Methods). Cases were defined as participants diagnosed with incident 
malignant neoplasm of the kidney or renal pelvis (ICD-O3 code C64/C65) who gave a blood 
sample at recruitment. In each independent cohort, one randomly selected control without 
history of kidney cancer was matched to each case based on age, sex and date of blood 




were matched to cases according to their age and date of blood draw (see Supplementary 
Methods), owing to inherent differences in demography and availability of controls. The study 
was approved by the International Agency for Research on Cancer (IARC) Ethics Committee.  
Metabolite data acquisition and quality control (QC) 
Plasma and serum samples from 2,614 participants (1,307 cases and 1,307 controls) were 
analysed. Samples from all cohorts were analysed using the Biocrates targeted mass 
spectrometry assay. Samples from EPIC and NSHDS (n=1,596) were additionally analysed 
using Metabolon’s untargeted mass spectrometry platform. Samples from matched case-
control pairs were assayed in adjacent wells (in random order), and in the same analytical 
batch. Laboratory personnel were blinded to case-control status of the samples. 
An overview of the QC pipeline is shown in Supplementary Figure S1. All the QC steps were 
performed for each cohort separately before pooling the data. 
Targeted metabolomics - Biocrates 
All samples from EPIC and MCCS were assayed at the International Agency for Research on 
Cancer (IARC), while samples from NSHDS, HUNT and the Estonian BB were assayed by the  
Metabolomics Core Facility of the Genome Analysis Center of the Helmholtz Zentrum 
München [32]. The targeted metabolomics approach was based on LC-ESI-MS/MS and FIA-
ESI-MS/MS measurements using the AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, 
Innsbruck, Austria). The assay allows simultaneous quantification of 188 metabolites using 10 
µL plasma or serum. Sample preparation and mass spectrometry measurements were 
performed as described in Supplementary Methods. The median intra- and inter-batch 




2.8%, respectively). The lower limits of detection (LODs) were set to three times the values of 
the zero samples (phosphate buffered saline solution).  
Values lower than the LLOQ, or higher than the ULOQ, as well as lower than batch-specific 
LOD (for compounds semi-quantified: acylcarnitines, glycerophospholipids (GPL), 
sphingolipids), were imputed with half of the LOD/LLOQ, or the ULOQ. For NSHDS, 
metabolites with internal standard out of range were left as missing (n=205). Metabolites 
with less than 100 values above LOD/LLOQ in any individual cohort were excluded from the 
analyses. In our samples, a total of 164 metabolites were retained for statistical analyses (30 
acylcarnitines, 21 amino acids, 10 biogenic amines, 88 GPLs, 14 sphingolipids and the sum of 
hexoses). In addition to individual metabolites, 22 ratios or sums selected for their capacity 
to provide detailed insight into a wide range of disorders of the metabolic disease spectrum 
were computed (listed in Supplementary Table S4). Among them, the Fischer’s ratio, a clinical 
indicator of liver metabolism and function, was calculated as the molar ratio of branched 
chain amino acids (leucine + isoleucine + valine) to aromatic amino acids (phenylalanine + 
tyrosine). Lower Fischer’s ratio values are associated with liver dysfunction. 
Untargeted metabolomics – Metabolon 
Untargeted metabolomic analyses were performed at Metabolon, Inc. (Durham, North 
Carolina, USA) on a platform consisting of four independent ultra-high performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. Detailed descriptions 
of the platform and workflow to identify features, including extraction of raw data, peak-
identification, and internal quality control (QC) processes can be found in the Supplementary 
Methods and in published work [33-35]. Samples from EPIC and NSHDS were processed as 
two independent experimental batches. The median intra-batch CV were 5% and 4% for EPIC 




A variety of curation procedures were carried out by Metabolon, Inc. to ensure that a high-
quality data set was made available for statistical analysis and data interpretation 
(Supplementary Methods). Each metabolite was rescaled to set the median equal to 1 and 
missing values imputed with the minimum observed value. Data returned for EPIC comprised 
a total of 1308 metabolite features, 982 of known identity (named biochemicals) and 326 
compounds of unknown structural identity (unnamed biochemicals). Data returned for 
NSHDS comprised a total of 1302 metabolite features, 979 of known identity (named 
biochemicals) and 323 compounds of unknown structural identity (unnamed biochemicals). 
A total of 1275 metabolites were available across the two datasets with the total number of 
unique metabolites reaching 1335. Metabolites were categorised by Metabolon, Inc. as 
belonging to one of eight mutually exclusive chemical classes: amino acids and amino acid 
derivatives (subsequently referred to as ‘amino acids'), carbohydrates, cofactors and 
vitamins, energy metabolites, lipids, nucleotides, peptides, or xenobiotics. An asterisk (*) at 
the end of the metabolite name indicates the metabolite identity has not been confirmed by 
comparison with an authentic chemical standard. After the exclusion of metabolites for which 
less than 100 participants had values recorded (86 and 176 for EPIC and NSHDS, respectively), 
1230 metabolite features remained for analysis (1222 and 1126 for EPIC and NSHDS, 
respectively; 1118 in common).  
Statistical analysis 
Primary statistical analysis: prospective observational analysis of circulating metabolites and 
kidney cancer risk 
Log-transformed and standardised (z-score) metabolite concentrations were used in all 
analyses. Crude conditional logistic regressions were performed to estimate the odds ratio 




metabolite concentrations, conditioning on the individual case-control sets. To consider 
multiple comparisons whilst accounting for the correlation between the different 
metabolites, we estimated the effective number of independent tests performed (ENT) as the 
number of principal components explaining more than 95% of the variance in our metabolite 
matrices. Metabolites with p-values equal or below 0.05/ENT in the pooled analyses and 
equal or below 0.05 in at least two cohorts independently, were deemed robustly associated 
with kidney cancer risk. For these metabolites, we carried out additional conditional logistic 
regressions adjusted for BMI, smoking history (smoking status: never, former, current 
smokers and pack years of smoking), lifetime alcohol consumption (in g/day) and 
hypertension (ever/never). To avoid comparing different sets of participants due to 
missingness in risk factor data, we restricted these analyses to study participants with 
complete risk factor information. 
To further characterise the epidemiological properties of the association between 
metabolites and kidney cancer risk, we also carried out conditional logistic regression 
stratified by age at blood collection, sex, country, BMI, waist-to-hip ratio, smoking status, 
alcohol consumption, hypertension and time to diagnosis (number of years between blood 
draw and diagnosis).  
Secondary statistical analysis: Mendelian randomization and profile comparison analyses 
We initially investigated pleiotropy among potential SNP instruments for the circulating 
metabolites associated with kidney cancer risk in prospective analyses (Biocrates and 
Metabolon) with a view to conducting a two-sample MR analysis for metabolites (as the 
exposure) and kidney cancer risk (as the outcome). SNP-metabolite associations were 
extracted from the largest GWASs currently available for circulating metabolites and included 




different metabolites, depending on the platform used in each contributing study) and 913 
Metabolon metabolites (N=14,296). Specifically, pleiotropy was assessed by estimating the 
variance explained in all metabolites by the single nucleotide polymorphisms (SNPs) (i.e. the 
potential ‘instruments’) associated with each of our candidate risk metabolites (see 
Supplementary methods for more details of how instruments were selected). Where the 
variance explained in other metabolites (i.e. those not associated with risk in the prospective 
analysis) was similar to that explained in the candidate risk metabolite we inferred low 
metabolite-specificity for current GWAS results, and thus violation of the MR assumptions 
necessary to infer potential single exposure causality. 
To evaluate the extent to which the metabolomic signature of disease risk could be explained 
by BMI we first conducted a two-sample MR analysis to provide estimates of the causal 
relationships between BMI and circulating metabolites (Biocrates and Metabolon). 549 
independent SNPs (R2<0.01) that were robustly associated with BMI at genome-wide 
significance were selected as instruments from the largest GWAS meta-analysis for BMI from 
the Genetic Investigation of Anthropometric Traits (GIANT) consortium (n= approximately 
700,000[37] see Supplementary Table S5). SNP-exposure associations were extracted from 
the BMI GWAS meta-analysis[37] and SNP-outcome associations were extracted from the 
metabolite GWAS described above. A BMI effect estimate was generated for each metabolite 
measured and calculated as an SD unit increase in log-transformed metabolite level per SD 
increment in BMI. The primary MR analysis was conducted using the inverse-variance 
weighted (IVW) method[38]. We performed the following sensitivity analyses to attempt to 
account for potential unbalanced horizontal pleiotropy: 1) MR-Egger regression to test overall 
directional pleiotropy and provide a valid causal estimate, taking into account the presence 




effect if at least 50% of the information in the analysis comes from variants that are valid 
instrumental variables. To account for multiple testing, we used the same p value threshold 
as used in our observational analyses (p<8.3x10-4 and p<1x10-4 for Biocrates and Metabolon, 
respectively).  
To examine the extent to which kidney cancer-associated metabolites are driven by BMI, we 
assessed the correlation between the kidney cancer-associated metabolite profile 
(metabolites associated with kidney cancer risk in the prospective observational analyses) and 
the BMI-associated metabolite profile (metabolites associated with BMI levels in the MR 
analyses) using Spearman rank correlation analyses. Effect estimates from both the 
prospective and MR analyses were divided by the standard error of the estimate before 
conducting the correlation analyses. 
Negative control analyses 
The presence or absence of overlap between metabolite profiles flagged by prospective 
analysis and those derived from BMI MR is only informative in the context of a null, or 
negative control comparator. To allow this, we repeated the profile comparison analysis 
described above (with BMI as the exposure) in an analysis in which we used dental disease as 
a negative control exposure (i.e. an exposure not likely to be a risk factor for kidney cancer) 
and one that we would therefore expect to deliver a null. This strategy of repeating an 
experiment under conditions which are expected to deliver a null result has previously been 
advocated within observational epidemiology [41]. In our analysis of the causal relationship 
between dental disease and circulating metabolites, 47 independent (R2<0.01) SNPs that 
were robustly associated at genome-wide significance (p<5x10-8) were selected from the 
largest GWAS for dental disease (n=487,823) (detailed information for instrumental variables 




were extracted from the largest dental disease GWAS meta-analysis[42] and SNP-outcome 
associations were extracted from the metabolite GWAS described above. Effect estimates 
were calculated as SD unit increase in metabolite levels per logOR increase in dental disease. 
Methods used in the two sample MR analyses were as described above. 
All MR analyses were performed using the TwoSample MR R package version 0.4.13 
(http://github.com/MRCIEU/TwoSampleMR) [43].  
Results 
Population characteristics and metabolites overview 
Demographic and baseline characteristics for the 1,305 cases and 1,305 matched controls are 
presented in Table 1. The mean age at diagnosis for cases was 65.6 years (SD=9.79) and cases 
were diagnosed on average 8 years after blood collection. The majority (58%) of samples were 
collected after fewer than 6 hours of fasting. Overall, 186 metabolites or ratios/sums of 
metabolites were measured using the Biocrates assay on 2,610 samples (all cohorts), and 
1,230 metabolites were measured using the Metabolon platform on 1,596 samples (EPIC and 
NSHDS cohorts). Mean concentrations of the 1,416 metabolites by case-control status are 
shown in Supplementary Table S7. 
Prospective observational analysis of circulating metabolites and kidney cancer risk  
We identified 25 metabolites robustly associated with kidney cancer risk (i.e. metabolites 
associated with risk after correction for multiple testing in the pooled analysis and nominally 
significant in at least 2 cohorts; Figure 2 and Table 2). Amongst these metabolites, 12 were 
measured with the Biocrates assay and 13 were measured with the Metabolon platform. Two 
metabolites - glutamate and 1-linoleoyl-GPC (18:2) (known as lysoPC a C18:2 in Biocrates) - 




glutamate OR: 1.34 in Biocrates and 1.39 in Metabolon; for 1-linoleoyl-GPC (18:2), OR: 0.77 
in Biocrates and 0.76 in Metabolon). Pearson correlations amongst risk-metabolites are 
displayed in Supplementary Figure S2.  
We found that increased concentrations of 14 individual GPLs were associated with reduced 
kidney cancer risk. These included 8 phosphatidylcholines (PC; overall p-values ranging from 
6x10-4 to 3x10-8), amongst which PC ae C34:3 had the strongest association (OR=0.75, 95% CI: 
0.68 to 0.83, p=2.61x10-8). Similar associations were identified for the lysophosphatidyl-
cholines, lysoPC a C18:1, and lysoPC a C18:2 (labelled as 1-linoleoyl-GPC (18:2) in Metabolon) 
(p-values between 1.60x10-5 and 9.65x10-7). Two plasmalogens were also inversely associated 
with risk, 1-(1-enyl-palmitoyl-2-oleoyl-GPC (P-16:0/18:1) (p=1.27x10-5) and 1-(1-enyl-
palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) (p=2.79x10-5), as well as the lysoplasmalogen 1-(1-
enyl-palmitoyl)-GPC (P-16:0) (p=8.32x10-6). 
Amongst 274 metabolites involved in amino acid metabolism, we found four positively 
associated with kidney cancer risk, including glutamate, formiminoglutamate, hydantoin-5-
propionate and the Fischer’s ratio (p-values between 1.25x10-4 and 5.11x10-7). For example, 
the relative odds of kidney cancer associated with a standard deviation increment in log-
transformed glutamate levels was estimated at 1.39 (95% CI: 1.20 - 1.60) when measured on 
the Metabolon platform. Another amino acid, cysteine-glutathione disulphide, was inversely 
associated with risk (OR: 0.77, 95% CI: 0.69 - 0.86, p=7.42x10-6). The two peptides gamma-
glutamylvaline (p=1.22x10-7) and gamma glutamylisoleucine (p=1.07x10-6), were positively 
associated with risk. Finally, we found beta-cryptoxanthin negatively associated with kidney 
cancer risk (OR: 0.73, 95%CI: 0.65, 0.83, p=4.83x10-7) while an unidentified metabolite (X-




fasting status of the samples (more vs less than 6 hours) did not modify the OR estimates for 
the identified risk metabolites (Supplementary Table S8).  
Associations with risk of kidney cancer for all metabolites analysed are presented in 
Supplementary Table S9.  
The influence of kidney cancer risk factors on kidney cancer-associated metabolites 
We assessed the extent to which known modifiable risk factors could explain the observed 
associations by multivariable analyses. For all 25 metabolites found to be associated with risk 
in the primary analysis, we found that adjustments for BMI partly attenuated the OR 
estimates for some metabolites, although they all remained at least nominally significant (i.e. 
p-value below 0.05, Table 2). The association most modified by adjustment for BMI was that 
of glutamate (from 1.34, 95%CI: 1.17-1.53, p=1.62x10-5 to 1.24, 95%CI: 1.08-1.42, p=2.46x10-
3), followed by PC ae C42:3 and PC aa C42:1 (OR increased by 6% for both metabolites: from 
0.82, 95%CI: 0.74-0.92, p=4.17x10-4  to  0.87, 95%CI: 0.78-0.98, p=1.75x10-2 and 0.83, 95%CI: 
0.75-0.93, p=6.27x10-4 to 0.88, 95%CI: 0.79-0.99, p=2.59x10-2 for PC ae C42:3 and PC aa C42:1, 
respectively). Conversely, association for PC ae C38:6 was not influenced by adjustment for 
BMI (OR:0.85, 95%CI: 0.77-0.93, p=5.06x10-4  to 0.86, 95%CI: 00.78-0.95, p=1.85x10-3). Results 
adjusted for all individual risk factors on participants with complete information on these risk 
factors are shown in Supplementary Table S10 (N=1,162 and 996 for Biocrates and 
Metabolon, respectively). Adjustment for smoking and alcohol consumption did not modify 
any OR by more than 1.5% and 1.2%, respectively, whereas adjusting for hypertension partly 
attenuated the associations of lysoPC a C18:1 and lysoPC a C18:2, albeit to a lesser extent 
than BMI (5% change for both). In fully adjusted models, risk associations remained nominally 




same direction as in the primary analysis, although, due to missing data for some risk factors, 
this analysis included only 581 and 498 case-control pairs for Biocrates and Metabolon, 
respectively.  
In stratified risk analyses by time to diagnosis (Supplementary Figures S3 to S27), several 
metabolites appeared to display a stronger risk-association closer to diagnosis, including 1-
(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) (heterogeneity p=0.02) (Supplementary 
Figure S15) and the metabolite of unknown structural identity X-12096 (heterogeneity 
p=0.02) that was measured on the Metabolon platform (Supplementary Figure S27). The 
lysophosphatidyl-choline lysoPC a C18:2, as measured by Biocrates, showed a stronger 
association when alcohol consumption was above the median compared to lower 
(heterogeneity p=0.03) (Supplementary Figure S6); this pattern was evident for the same 
metabolite measured in Metabolon but was not statistically significant (heterogeneity p=0.3) 
(Supplementary Figure S18).  
Two sample Mendelian randomization and profile comparison analyses 
We identified genetic instruments for 17 of the 25 risk metabolites but observed substantial 
pleiotropy for the instruments defined for 16 of the 17 instrumented metabolites. The total 
variance explained from a risk-metabolite’s instruments was typically similar across classes of 
metabolite (lipids and 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2), for example), and 
far from specific to the given risk-metabolite being instrumented. Further, the variance 
explained was often higher for an alternative metabolite compared to the risk-metabolite 
(see Supplementary Figures S28 to S44). Following these observations, we chose not to carry 
out a formal MR analysis of the relation between individual metabolites and kidney cancer 




Rather, to complement the risk analyses, and to gain further understanding of how BMI – the 
leading modifiable risk factor of kidney cancer – might explain our findings, we conducted a 
two-sample MR analysis to evaluate the extent to which the measured metabolites are driven 
by differences in BMI. Using the IVW method, 60 metabolites (22 Biocrates and 38 
Metabolon) were associated with BMI. In an MR framework, there was consistent evidence 
between both platforms that BMI was associated with decreased concentrations of many 
GPLs and increased concentrations of several amino acids and nucleotides, as well as 
acylcarnitines, sphingomyelins and several metabolites of unknown identity (Figure S45). 
Estimates from MR-Egger and weighted median analyses were consistent with the IVW 
estimates (Supplementary Table S11 and S12).  
When comparing the metabolic profile of kidney cancer (metabolites associated with kidney 
cancer risk in the prospective analyses) and BMI (metabolites associated with BMI levels in 
the MR analyses), we observed moderate correlation between the BMI-driven metabolite 
profile and metabolite profile associated with kidney cancer risk (Figure 3) (r=0.53, p=2.2x10-
6 for Biocrates metabolites and r=0.36, p=2.2x10-6 for Metabolon metabolites). Specifically, 
elevated BMI appeared to decrease levels of several GPLs that were also found inversely 
associated with kidney cancer risk, including 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-
16:0/18:2)*, 1-linoleoyl-GPC (18:2) (lysoPC a C18:2), lysoPC a C18:1 and PC ae C34:3. For 
instance, one SD increment in BMI was associated with a 0.17 SD decrease in 1-(1-enyl-
palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels ([ßBMI], p=3.4x10-5). We also found that BMI 
was associated with increased levels of glutamate (ßBMI: 0.12, p=1.5x10-3), which was 
positively associated with kidney cancer risk. Several metabolites associated with kidney 
cancer risk in our prospective analysis did not appear to be strongly influenced by BMI, but 




directionally concordant (i.e. positively correlated) but with the effect size estimates from the 
BMI MR being closer to the null than those seen in the observational analysis. Conversely, 
some of the metabolites that were most strongly affected by BMI (e.g. phenylalanine and 
valine), were not associated with kidney cancer risk. 
Negative control analyses 
There was little evidence that genetic predisposition to dental disease influenced circulating 
metabolite levels with no metabolites reaching our pre-determined threshold for a 
statistically significant association (Supplementary Table S13 and S14). We observed low 
correlation between the dental disease-metabolite estimates from MR analyses and the 
kidney cancer-metabolite estimates from the prospective analysis for both Biocrates 
metabolites (r=0.15, p=0.06) and Metabolon (r=0.12, p=0.002) (Supplementary Figure S46). 
None of the 25 metabolites that were associated with kidney cancer risk in prospective 
analyses were associated with dental disease from the MR analyses (Supplementary Figure 
S46). These findings suggest that when the profile comparison analysis is conducted using a 
hypothetically unrelated exposure (dental disease) we see no meaningful relationship 
between metabolite associations from the prospective analysis and the MR.  
 
Discussion 
This study describes the relationship between the pre-diagnostic blood-metabolome and risk 
of developing kidney cancer based on data from five longitudinal population cohorts. This is 
the first comprehensive metabolomics analysis of incident kidney cancer to be conducted 
using a prospective design, and as such, complements existing work characterising the 




metabolites in relation to the occurrence of kidney cancer using two complementary 
analytical methods and observed 25 metabolites to be robustly associated with risk. These 
metabolites included 14 GPLs inversely associated with risk, five amino acids positively 
associated, and one inversely associated with risk, as well as risk associations for a carotenoid, 
two peptides, a nucleotide and an unidentified feature. Results of an MR analysis designed to 
evaluate the extent to which BMI influences the key risk-associated metabolites, suggest that 
differences in BMI may be responsible for part of the metabolite profile associated with the 
development of kidney cancer.  
The majority of metabolites found to be associated with kidney cancer risk in this study can 
be classified as glycerophospholipids (GPLs). GPLs are the main component of cell membranes 
and are essential for maintaining cellular structure and for regulating cell signalling. The 
circulating metabolite associations we see here pre-diagnosis appear to intersect with the 
known cellular metabolic programming observed within kidney tumour tissue. For example, 
it has been proposed that clear cell RCC cells use exogenous lipids for membrane formation 
and cell signalling [44]. The relationship between lipid metabolites and prospective kidney 
cancer risk reported in our study could, theoretically, be capturing increased uptake of lipid 
metabolites by preclinical kidney carcinogenesis.  
GPLs can be broadly classified into two types based on their biochemical structure – diacyl 
(aa) or acyl-alkyl (ae) – and can be further characterised according to their lipid side-chain 
composition, specifically the number of carbons and their degree of (un)saturation (number 
of double bonds). The association of a subset of long chain unsaturated (mainly acyl-alkyl) 
phosphatidylcholines (PCs), lysophophatidylcholines (LPCs) and plasmalogens with reduced 
kidney cancer risk is consistent with some limited existing literature. Specifically, lower levels 




cancer patients compared to control participants,[17] and numerous studies have found 
decreased LPCs in both tumour and normal kidney tissues,[27,45,46] as well as in the 
circulation of kidney cancer patients [18,47]. The mechanisms underpinning these 
associations are not well-understood, but some of these molecules (e.g. plasmalogens) have 
been proposed as antioxidants[48]. Low levels of plasmalogens in cancer patients have been 
proposed as a potential mechanism by which increased oxidative stress could drive cancer 
progression [49]. 
We assessed the extent to which known risk factors could explain the observed metabolite 
associations and observed that adjusting for BMI – the main modifiable risk factor for kidney 
cancer – partially attenuated (less than 9% change in OR) the risk association for some specific 
metabolites. To further understand the relation with BMI for the kidney cancer risk-
associated metabolites, we estimated the causal influence of BMI on metabolite levels using 
Mendelian randomization. This analysis clearly demonstrated that some – but not all – 
metabolites inversely associated with kidney cancer risk are also decreased by elevated BMI 
(e.g. several GPLs), whereas other metabolites positively associated with risk (e.g. glutamate), 
are also increased by elevated BMI. The association of long chain unsaturated (mainly acyl-
alkyl) GPLs with both lower risk of RCC and lower BMI is consistent with extensive literature 
linking lower levels of these and similar molecules to a range of common diseases that include 
a metabolic component such as obesity and hypertension,[50-52] type 2 diabetes,[53] type 1 
diabetes development[54] and non-alcoholic fatty liver disease [55]. 
Glutamate was found to be positively associated with both kidney cancer risk and BMI and 
was also the metabolite for which adjusting for BMI resulted in the greatest attenuation in its 
OR estimate. Glutamate and glutamine are both found to be increased in kidney tumour 




relevant to disease development and those whose levels are perturbed in the disease state 
[10,56]. Consistent with our findings, glutamate has previously been shown to be increased 
in visceral obesity[57,58] and glutamine-derived glutamate has been linked to tumour cell 
metabolism[59] with renal cell carcinoma being no exception [60]. α-Ketoglutarate, 
generated from glutamine-derived glutamate, enters the tricarboxylic acid (TCA) cycle 
providing both energy and biosynthetic intermediates [61]. A large intracellular glutamate 
pool is also important for nonessential amino acid synthesis in addition to cellular redox 
regulation [61]. Two previous nuclear magnetic resonance (NMR)-based studies found lower 
levels of glutamine in serum of kidney cancer cases taken at diagnosis compared to controls 
[16,17]. Whilst we did not identify a robust association of glutamine in our study, the point 
estimate was consistent with a weak inverse association with risk of kidney cancer. 
A final overarching observation was that in comparison with previously published prospective 
metabolomics analyses on other cancer sites,[62-64] the sheer number of metabolites found 
to be associated with risk in the current study suggests that the blood metabolome is 
particularly important in the aetiology of kidney cancer. 
Strengths, limitations and prospects for future studies 
The chief strength of our study was the design of the primary risk analysis wherein control 
subjects were individually matched to incident kidney cancer cases with pre-diagnostic blood 
samples from five independent population cohorts, a design that minimized differential bias 
and allowed for identification of novel and robust risk metabolites of kidney cancer. The use 
of two complementary metabolomics platforms also increased the overall coverage of the 
metabolome. The well-characterized cohorts offered the opportunity to carefully assess the 




associated metabolites, as well as the robustness of their risk associations across the 
independent cohort studies. Well-designed prospective studies can provide compelling 
evidence in favour of a role of molecular risk factors in cancer aetiology, but residual 
confounding from imperfectly measured risk factors may still bias the association estimates. 
We therefore complemented the main risk analysis with a genetic analysis to assess the 
influence of BMI on the identified risk metabolites. We believe that this independent analysis 
provided important independent evidence when interpreting the relation between the 
identified risk metabolites and kidney cancer risk in the context of BMI – the principal risk 
factor of kidney cancer. 
Limitations of our study include the presence of measurement error in the (semi-) 
quantification of metabolites. However, by using well-established platforms with built-in 
validation procedures along with randomisation schemes to ensure any batch variation was 
orthogonal to the outcome of interest (in this case kidney cancer case status), we can be 
confident there was no systematic bias in our estimates as a result of measurement error. In 
addition, the consistency in estimates we see for metabolites that appear on both platforms 
provides increased confidence in our results, but we note that statistical power to identify 
risk metabolites exclusive to the Metabolon platform was lower than for metabolites 
exclusive to the Biocrates platform due to the lower sample size. In this study, we focused on 
those metabolites that demonstrated consistency in risk associations across the five 
participating cohorts. Whilst this approach ensured the robustness of the estimates, any risk 
marker present in specific populations would not be highlighted. Although we only measured 
metabolite levels at a single time point, we do not believe this represents a major limitation 
as the majority of measured metabolites have a high within person stability over time (stable 




on body composition. It is possible that some individual risk markers may reflect a certain 
adiposity distribution that is specifically strongly associated with kidney cancer risk. Whilst 
the current literature on kidney cancer aetiology does not highlight any specific aspect of 
obesity as being particularly important in kidney cancer aetiology, evaluating the identified 
risk markers in relation to detailed body composition (e.g. using DEXA scan data) represents 
an appealing future focus of our kidney cancer research. The remaining limitations relate to 
the generalisability of our findings. Given evidence for specific metabolic alterations by kidney 
cancer histotype [10], it is possible that kidney cancer subtypes have different dependencies 
on circulating metabolites. In this case, findings from this study are likely most relevant to the 
major histological subtype – clear cell RCC – which made up 71% of kidney cancer cases. 
Furthermore, our study does not inform on the extent to which the identified risk markers 
translate to populations of non-European descent. Addressing these limitations should 
constitute an important focus for future studies addressing the role of the blood metabolome 
in the aetiology of kidney cancer.  
Whilst the results of our prospective risk analysis are consistent with circulating metabolites 
playing an important role in kidney cancer aetiology, it is appealing to complement such 
observational analyses with MR studies to further inform causal inference. However, we 
chose not to carry out an MR analysis on kidney cancer risk for individual metabolites for a 
number of reasons related to characteristics specific to circulating metabolites. Firstly, owing 
to high correlational structure of many metabolites, few SNPs have been found associated 
with specific metabolites, leading to pleiotropic instruments for most metabolites [36]. 
Secondly, there is a high degree of pleiotropy for metabolite-associated SNPs with modifiable 
risk factors and other disease endpoints. That few metabolites have a sufficient number of 




these biases is not possible (e.g. MR-Egger and MR-PRESSO), nor is the use of techniques 
designed to evaluate the effect of multiple correlated exposures (e.g. multivariable MR [68]). 
Whilst the genetic architecture of blood metabolites is complicated for the reasons outlined 
above, there are hundreds of independent SNPs robustly associated with BMI [37] and this 
gave us greater confidence in the application of this analysis [69]. Better characterizing of the 
genetic architecture of circulating metabolites together with methodological advancements 
may allow for more robust causal inference in future metabolomics studies. 
 
Conclusions 
This study points to a particularly important role of the blood metabolome in kidney cancer 
aetiology, specifically by identifying positive risk associations for several amino acids, as well 
as negative risk associations with multiple lipids, including PCs, LPCs and plasmalogens. 
Downstream analyses indicated that some – but not all – risk metabolites are influenced by 
BMI, which partly explains their associations with kidney cancer risk, whereas the risk 
associations for other metabolites could not be explained by known risk factors. These results 
provide important insight into the metabolic pathways underpinning the central role of 
obesity in kidney cancer aetiology, and clues to novel pathways involved in kidney cancer 
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Table 1. Population characteristics of the 2,610 kidney cancer cases and controls from 5 
independent cohorts with pre-diagnostic blood samples included in our analyses. 
  Cases Controls 
  
mean (SD) or N 
(%) 
mean (SD) or N 
(%) 
Total 1305 1305 
   
Age at blood collection (years) 57.6 (10.1) 57.6 (10.1) 
   
Length of follow-up from blood collection (years) 7.95 (4.98) - 
   
Histology   
Clear Cell 931 (71.3) - 
Other 282 (21.6) - 
Unknown 92 (7.1) - 
   
Sex   
Male 725 (55.6) 725 (55.6) 
Female 580 (44.4) 580 (44.4) 
   
Cohort   
EPIC 634 (48.6) 634 (48.6) 
Estonian Biobank 115 (8.8) 115 (8.8) 
HUNT 254 (19.5) 254 (19.5) 
MCCS 139 (10.6) 139 (10.6) 
NSHDS 163 (12.5) 163 (12.5) 
   
Education   
None 43 (3.3)  52 (4)  
Primary School 468 (35.9)  456 (34.9)  
Technical School 233 (17.9)  222 (17)  
Secondary School 239 (18.3)  236 (18.1)  
University 216 (16.6)  242 (18.5)  
Unknown 106 (8.1)  97 (7.4)  
   
Body Mass Index (BMI)   
mean (SD) 27.79 (4.62) 26.95 (4.28) 
   
BMI classes   
<18.5 6 (0.5)  6 (0.5)  
[18.5-25[ 364 (27.9)  458 (35.1)  
[25-30[ 596 (45.7)  581 (44.5)  
>=30 335 (25.7)  254 (19.5)  
Unknown 4 (0.3)  6 (0.5)  
   
   




Never 553 (42.4) 603 (46.2) 
Former 418 (32) 445 (34.1) 
Current 315 (24.1) 233 (17.9) 
Unknown 19 (1.5) 24 (1.8) 
   
Smoking quantity   
Pack-years; mean (SD) 11.77 (17.13) 9.63 (15.34) 
min-max 0.00-153.45 0.00-100.00 
   
Alcohol consumption (g/d)   
mean (SD) 13.85 (25.14) 14.87 (29.61) 
   
Diabetes   
No 1069 (81.9)  1099 (84.2)  
Yes 80 (6.1)  54 (4.1)  
Unknown 156 (12)  152 (11.7)  
   
Hypertension   
No 612 (46.9)  718 (55)  
Yes 433 (33.2)  333 (25.5)  
Unknown 260 (19.9)  254 (19.5)  
   
Fasting status   
Fasting for less than 6 hours 768 (58.8) 759 (58.2) 
Fasting for 6 hours or more 476 (36.5) 497 (38.1) 
Unknown 61 (4.7) 49 (3.7) 
BMI: Body Mass Index; EPIC: The European Prospective Investigation into Cancer and Prevention; Estonian BB: University 
of Tartu- Estonian Biobank; HUNT: The Trøndelag Health Study; MCCS: The Melbourne Collaborative Cohort Study; NSHDS: 







Table 2. Metabolites robustly associated with kidney cancer risk. 
  Crudea  Adjusted for BMIb 
Metabolite Name Class Npairs OR 95%CI P-value  Npairs OR 95%CI P-value 
Biocrates           
Glutamate Amino Acid 1300 1.34 1.17-1.53 1.62E-05  1290 1.24 1.08-1.42 2.46E-03 
Fischer's ratio Amino Acid (ratio) 1300 1.18 1.09-1.29 1.25E-04  1290 1.14 1.04-1.24 5.02E-03 
PC ae C34:3 Glycerophospholipids 1304 0.75 0.68-0.83 2.61E-08  1294 0.79 0.71-0.88 1.05E-05 
lysoPC a C18:2 Glycerophospholipids 1304 0.77 0.70-0.86 9.65E-07  1294 0.81 0.73-0.90 1.35E-04 
PC ae C34:2 Glycerophospholipids 1304 0.78 0.70-0.87 8.47E-06  1294 0.82 0.73-0.91 4.00E-04 
lysoPC a C18:1 Glycerophospholipids 1304 0.77 0.69-0.87 1.60E-05  1294 0.81 0.72-0.92 8.04E-04 
PC ae C40:1 Glycerophospholipids 1304 0.81 0.73-0.90 4.57E-05  1294 0.84 0.76-0.93 8.96E-04 
PC ae C32:2 Glycerophospholipids 1304 0.78 0.69-0.89 1.27E-04  1294 0.81 0.72-0.92 1.31E-03 
PC ae C36:3 Glycerophospholipids 1304 0.82 0.73-0.91 2.12E-04  1294 0.85 0.76-0.95 3.24E-03 
PC ae C42:3 Glycerophospholipids 1304 0.82 0.74-0.92 4.17E-04  1294 0.87 0.78-0.98 1.75E-02 
PC ae C38:6 Glycerophospholipids 1304 0.85 0.77-0.93 5.06E-04  1294 0.86 0.78-0.95 1.85E-03 
PC aa C42:1 Glycerophospholipids 1304 0.83 0.75-0.93 6.27E-04  1294 0.88 0.79-0.99 2.59E-02 
Metabolon           
Formiminoglutamate Amino Acid 798 1.34 1.20-1.50 5.11E-07  794 1.28 1.14-1.45 4.23E-05 
Glutamate Amino Acid 798 1.39 1.20-1.60 5.79E-06  794 1.30 1.11-1.51 8.02E-04 
Cysteine-glutathione disulfide Amino Acid 798 0.77 0.69-0.86 7.42E-06  794 0.79 0.70-0.89 6.99E-05 
Hydantoin-5-propionate Amino Acid 798 1.25 1.12-1.39 6.17E-05  794 1.22 1.09-1.36 3.76E-04 
Beta-cryptoxanthin Cofactors and Vitamins 798 0.73 0.65-0.83 4.83E-07  794 0.76 0.67-0.86 1.81E-05 
1-linoleoyl-GPC (18:2) Glycerophospholipids 798 0.76 0.67-0.86 7.03E-06  794 0.79 0.70-0.89 2.04E-04 
1-(1-enyl-palmitoyl)-GPC (P-16:0)* Glycerophospholipids 798 0.73 0.64-0.84 8.32E-06  794 0.77 0.67-0.88 1.71E-04 
1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)* Glycerophospholipids 798 0.79 0.71-0.88 1.27E-05  794 0.83 0.74-0.93 1.41E-03 
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* Glycerophospholipids 798 0.80 0.72-0.89 2.79E-05  794 0.84 0.76-0.94 1.61E-03 
N1-methyladenosine Nucleotide 798 1.40 1.23-1.60 6.50E-07  794 1.35 1.18-1.55 8.74E-06 
Gamma-glutamylvaline Peptide 798 1.38 1.23-1.56 1.22E-07  794 1.32 1.17-1.49 1.24E-05 
Gamma-glutamylisoleucine* Peptide 798 1.40 1.22-1.61 1.07E-06  794 1.33 1.15-1.53 1.01E-04 
X – 12096 Unknown 798 1.33 1.17-1.51 9.97E-06  794 1.27 1.12-1.45 2.40E-04 
BMI: Body Mass Index; CI: Confidence Interval; ENT: Effective Number of Test; Npairs: number of case control pairs included in the analyses; OR: Odds Ratio; * metabolite identity not yet confirmed by 




a: Odds ratios and confidence intervals were estimated for 1 SD of log transformed metabolite levels by logistic regression conditioned on case set; b: Odds ratios and confidence intervals were 
estimated for 1 SD of log transformed metabolite levels by logistic regression conditioned on case set and adjusted for Body Mass Index; Estimated ENT are 60 and 499 for Biocrates and Metabolon 
metabolites, respectively. P-values threshold are thus 8.33E-04 and 1.00E-04 for Biocrates and Metabolon metabolites, respectively; p-values below 0.05/ENT in the pooled analyses and at least 






Figure 1.  Conceptual framework of the study design. This study includes three main analytical 
steps: i) the investigation of the associations between circulating levels of metabolites and kidney 
cancer risk using pre-diagnostic measurements in a case-control study nested within multiple 
large-scale prospective cohorts; ii) the assessment of the causal effect of body mass index, the 
leading modifiable risk factor for kidney cancer, on circulating metabolites levels; iii) the 




   
 
BMI: Body Mass Index; EPIC: The European Prospective Investigation into Cancer and Prevention; Estonian BB: University of Tartu- 
Estonian Biobank; HUNT: The Trøndelag Health Study; LC-MS: liquid chromatography-tandem mass spectrometry; MCCS: The 
Melbourne Collaborative Cohort Study; MR: Mendelian Randomization; NSHDS: Northern Sweden Health and Disease study; SNP: 
single-nucleotide polymorphism. 
The orange X’s indicate the time at which a subject is diagnosed with kidney cancer when his follow-up is stopped. Controls have 
been selected amongst subjects free of cancer at the time their matched case was diagnosed. 
Metabolites from all samples have been measured on the Biocrates platform while only samples from EPIC and NSHDS cohorts 








Figure 2. Volcano plot depicting the association between circulating metabolites measured by 
either Biocrates (triangle) or Metabolon (dots) with kidney cancer risk in five prospective 
cohorts. Metabolites that are labelled have a p value below the threshold (p<0.05/Effective 




ENT: Effective Number of Test; OR: Odds Ratio; SD: Standard Deviation. 
* metabolite identity not yet confirmed by comparison with an authentic chemical standard 
Odds ratios and confidence intervals were estimated for 1 SD of log transformed metabolite levels by logistic regression 
conditioned on case set. Estimated ENT are 60 and 499 for Biocrates and Metabolon metabolites, respectively. P-values threshold 





Figure 3. Scatter plot comparing the metabolite profile associated with kidney cancer from 
prospective observational analyses with the BMI-driven metabolite profile from MR analyses. 
Metabolites that are labelled have a p value below the threshold (p<0.05/Effective number of 
tests (ENT)) in the prospective pooled analyses and are nominally significant in at least 2 cohorts 
separately. Metabolites measured by the Biocrates platform that are below the p value threshold 
are represented by triangles, those measured by the Metabolon platform that are below the p 
value threshold are represented by dots and those that are measured by either the Biocrates or 




MR: Mendelian Randomization; OR: Odds Ratio; SE: Standard Error. 
* metabolite identity not yet confirmed by comparison with an authentic chemical standard 
On the y-axis, the OR and SE were derived from the logistic regression analyses conditioned on case set estimating the associations 
between circulating metabolites and kidney cancer risk in five prospective cohorts.  
On the x-axis, the beta and SE were derived from the mendelian randomization analyses evaluating the effect of BMI on circulating 
metabolites levels. 
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State specific objectives, including any 
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and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
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Describe any efforts to address potential sources 
of bias 
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Selection of genetic variants is described in Section “Secondary 
statistical analysis: Mendelian randomization and profile 
comparison analyses”   
5. Assumptions: Explicitly state assumptions for the main analysis (e.g. relevance, 
exclusion, independence, homogeneity) as well assumptions for any additional or 
sensitivity analysis. 
Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”; paragraph 1 and 2 
6. Statistical methods main analysis 
Describe statistical methods and statistics used. 
a) Describe how quantitative variables were handled in the analyses (i.e., scale, units, 
model). 
b) Describe the process for identifying genetic variants and weights to be included in 
the 
analyses (i.e, independence and model). Consider a flow diagram. 
c) Describe the MR estimator, e.g. two-stage least squares, Wald ratio, and related 
statistics. 
Detail the included covariates and, in case of two-sample MR, whether the same 
covariate set was used for adjustment in the two samples. 
d) Explain how missing data were addressed. 
e) If applicable, say how multiple testing was dealt with. 
a, b, c) Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”   
d, e) Not applicable to our study 
7. Assessment of assumptions: Describe any methods used to assess the assumptions 
or justify their validity. 
Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”; paragraph 1 and 2 
8.Sensitivity analyses: Describe any sensitivity analyses or additional analyses 
performed. 
Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”; paragraph 1 and 2 
9. Software and pre-registration 
a) Name statistical software and package(s), including version and settings used. 
b) State whether the study protocol and details were pre-registered (as well as when 
and 
where). 
a) Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses” 
  
b) Methods, Section “Analytical strategy”  
Results 
 
10. Descriptive data 
a) Report the numbers of individuals at each stage of included studies and reasons for 
exclusion. Consider use of a flow-diagram. 
b) Report summary statistics for phenotypic exposure(s), outcome(s) and other relevant 
variables (e.g. means, standard deviations, proportions). 
c) If the data sources include meta-analyses of previous studies, provide the number of 
studies, their reported ancestry, if available, and assessments of heterogeneity across 
these studies. Consider using a supplementary table for each data source. 
d) For two-sample Mendelian randomization: 
i. Provide information on the similarity of the genetic variant-exposure associations 
between the exposure and outcome samples. 
ii. Provide information on extent of sample overlap between the exposure and outcome 
data sources. 
a) Methods, Section “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”   
b) Supplementary Table S5 and S6 
c) Methods, “Secondary statistical analysis: Mendelian 
randomization and profile comparison analyses”  and 
Supplementary Methods, Section “Data sources for Mendelian 
randomization analyses”  
d) Supplementary Methods, Section “Data sources for Mendelian 
randomization analyses”  
11. Main results 
a) Report the associations between genetic variant and exposure, and between genetic 
variant and outcome, preferably on an interpretable scale (e.g. comparing 25th and 
75th percentile of allele count or genetic risk score, if individual-level data available). 
b) Report causal effect estimate between exposure and outcome, and the measures of 
uncertainty from the MR analysis. Use an intuitive scale, such as odds ratio, or relative 
risk, per standard deviation difference. 
c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time-period. 
d) Consider any plots to visualize results (e.g. forest plot, scatterplot of associations 
between genetic variants and outcome versus between genetic variants and exposure). 
Our results are given in terms of betas and confidence intervals 
throughout the results section. We visualize results using a volcano 
plot in Supplementary Figure S45 and a scatter plot in Figure 3 and 
Supplementary Figure S46 
12. Assessment of assumptions 
a) Assess the validity of the assumptions. 
b) Report any additional statistics (e.g., assessments of heterogeneity, such as I2, Q 
statistic). 
We assessed the validity using sensitivity analyses such as MR-Egger 
and weighted median analyses, described in the "Two sample 
Mendelian randomization and profile comparison analyses" section 
of the results section and presented in Supplementary Table S11 
and S12. 
13. Sensitivity and additional analyses 
a) Use sensitivity analyses to assess the robustness of the main results to violations of 
the assumptions. 
b) Report results from other sensitivity analyses (e.g., replication study with different 
dataset, analyses of subgroups, validation of instrument(s), simulations, etc.). 
c) Report any assessment of direction of causality (e.g., bidirectional MR). 
d) When relevant, report and compare with estimates from non-MR analyses. 
e) Consider any additional plots to visualize results (e.g., leave-one-out analyses). 
Results, "Two sample Mendelian randomization and profile 
comparison analyses" and Supplementary Table S11 and S12. 
Discussion 
 
14. Key results Discussion, Paragraph 1 
15. Limitations 
Discuss limitations of the study, taking into account the validity of the MR assumptions, 
other sources of potential bias, and imprecision. Discuss both direction and magnitude 
of any potential bias, and any efforts to address them. 
Discussion, Section “Strengths, limitations and prospects for future 
studies”   
16. Interpretations 
a) Give a cautious overall interpretation of results considering objectives and 
limitations. 
Compare with results from other relevant studies. 
b) Discuss underlying biological mechanisms that could be modelled by using the 
genetic 
variants to assess the relationship between the exposure and the outcome. 
c) Discuss whether the results have clinical or policy relevance, and whether 
interventions 
could have the same size effect. 
 
a, b) Discussion, Paragraph 2-4 
c) Conclusion  
17.            Generalizability: 
Discussion, Section “Strengths, limitations and prospects for future 
studies”  
18.            Funding:  Funding 
19.            Data and data sharing: Data availability statement 
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Supplementary Figure S1. Overview of the quality control pipelines used for the 
metabolite measurements pre-processing 
 
 
EPIC: The European Prospective Investigation into Cancer and Prevention; Estonian BB: University of Tartu- Estonian 
Biobank; HUNT: The Trøndelag Health Study; MCCS: The Melbourne Collaborative Cohort Study; NSHDS: Northern Sweden 
Health and Disease study. 

























Corr: Pearson correlation coefficient
 
 
Supplementary Figures S3 to S27. Forest plots depicts the kidney cancer risk 
association for each metabolite deemed robustly associated with kidney cancer risk, 
stratified by specific risk factors.  
 
Supplementary Figure S3. Forest plots depicts the kidney cancer risk association for the 
Fischer’s ratio stratified by kidney cancer risk factors. 
 
BMI: Body Mass Index; CI: Confidence Interval; d: days; g: grams; N.: number of participants; OR: Odds Ratio.  
The Fischer’s ratio is a clinical indicator of liver metabolism and function, was calculated as the molar ratio of branched 
chain amino acids (leucine + isoleucine + valine) to aromatic amino acids (phenylalanine + tyrosine). Lower Fischer’s ratio 
values are associated with liver dysfunction.  
 
 
Supplementary Figure S4. Forest plots depicts the kidney cancer risk association for 
glutamate (Biocrates), stratified by risk factors.  
 




Supplementary Figure S5. Forest plots depicts the kidney cancer risk association for lysoPC a 
C18:1, stratified by risk factors.  
 




Supplementary Figure S6. Forest plots depicts the kidney cancer risk association for lysoPC a 
C18:2, stratified by risk factors.  
 




Supplementary Figure S7. Forest plots depicts the kidney cancer risk association for PC aa 
C42:1, stratified by risk factors.  
 




Supplementary Figure S8. Forest plots depicts the kidney cancer risk association for PC ae 
C32:2, stratified by risk factors.  
 




Supplementary Figure S9. Forest plots depicts the kidney cancer risk association for PC ae 
C34:2, stratified by risk factors.  
 




Supplementary Figure S10. Forest plots depicts the kidney cancer risk association for PC ae 
C34:3, stratified by risk factors.  
 




Supplementary Figure S11. Forest plots depicts the kidney cancer risk association for PC ae 
C36:3, stratified by risk factors.  
 




Supplementary Figure S12. Forest plots depicts the kidney cancer risk association for PC ae 
C38:6, stratified by risk factors.  
 




Supplementary Figure S13. Forest plots depicts the kidney cancer risk association for PC ae 
C40:1, stratified by risk factors.  
 




Supplementary Figure S14. Forest plots depicts the kidney cancer risk association for PC ae 
C42:3, stratified by risk factors.  
 




Supplementary Figure S15. Forest plots depicts the kidney cancer risk association for 1-(1-
enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)*, stratified by risk factors.  
 
BMI: Body Mass Index; CI: Confidence Interval; d: days; g: grams; N.: number of participants; OR: Odds Ratio. 




Supplementary Figure S16. Forest plots depicts the kidney cancer risk association for 1-(1-
enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)*, stratified by risk factors.  
 
BMI: Body Mass Index; CI: Confidence Interval; d: days; g: grams; N.: number of participants; OR: Odds Ratio. 




Supplementary Figure S17. Forest plots depicts the kidney cancer risk association for 1-(1-
enyl-palmitoyl)-GPC (P-16:0)*, stratified by risk factors.  
 
BMI: Body Mass Index; CI: Confidence Interval; d: days; g: grams; N.: number of participants; OR: Odds Ratio. 




Supplementary Figure S18. Forest plots depicts the kidney cancer risk association for 1-
linoleoyl-GPC (18:2), stratified by risk factors.  
 




Supplementary Figure S19. Forest plots depicts the kidney cancer risk association for beta-
cryptoxanthin, stratified by risk factors.  
 




Supplementary Figure S20. Forest plots depicts the kidney cancer risk association for 
cysteine-glutathione disulfide, stratified by risk factors.  
 




Supplementary Figure S21. Forest plots depicts the kidney cancer risk association for 
formiminoglutamate, stratified by risk factors.  
 




Supplementary Figure S22. Forest plots depicts the kidney cancer risk association for gamma-
glutamylisoleucine*, stratified by risk factors.  
 
BMI: Body Mass Index; CI: Confidence Interval; d: days; g: grams; N.: number of participants; OR: Odds Ratio. 




Supplementary Figure S23. Forest plots depicts the kidney cancer risk association for gamma-
glutamylvaline, stratified by risk factors.  
 




Supplementary Figure S24. Forest plots depicts the kidney cancer risk association for 
glutamate (Metabolon), stratified by risk factors.  
 




Supplementary Figure S25. Forest plots depicts the kidney cancer risk association for 
hydantoin-5-propionate, stratified by risk factors.  
 




Supplementary Figure S26. Forest plots depicts the kidney cancer risk association for N1-
methyladenosine, stratified by risk factors.  
 




Supplementary Figure S27. Forest plots depicts the kidney cancer risk association for X-
12096, stratified by risk factors.  
 






Supplementary Figures S28-44.  Scatter plots of the cumulative variance explained in the Metabolon/Biocrates metabolites by the genome-wide 
significant (p<5x10-8) independent (R2<0.01) single nucleotide polymorphisms (SNPs) for the specified risk metabolite (labelled in red) 
Supplementary Figure S28. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for cysteine-glutathione disulfide (Metabolon). 





Supplementary Figure S29. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for Hydantoin-5-propionate (Metabolon). 




Supplementary Figure S30. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for 1-linoleoyl-GPC (18:2) (Metabolon). 







Supplementary Figure S31. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for 1-(1-enyl-palmitoyl)-GPC (P-16:0) (Metabolon). 




Supplementary Figure S32. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1) (Metabolon). 





Supplementary Figure S33. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) (Metabolon). 




Supplementary Figure S34. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for N1-methyladenosine (Metabolon). 







Supplementary Figure S35. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C34:3 (Biocrates). 
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Supplementary Figure S36. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for lysoPC a C18:2 (Biocrates). 
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Supplementary Figure S37. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C34:2 (Biocrates). 
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Supplementary Figure S38. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for lysoPC a C18:1 (Biocrates). 
















0.0 0.3 0.6 0.9 1.2


















Supplementary Figure S39. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C40:1 (Biocrates). 
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Supplementary Figure S40.  Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C32:2 (Biocrates). 
Metabolites that are labelled have a p value below the genome-wide significance threshold (p<5E-08). 
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Supplementary Figure S41. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C36:3 (Biocrates). 























Supplementary Figure S42.  Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C42:3 (Biocrates). 
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Supplementary Figure S43.  Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC ae C38:6 (Biocrates).  
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Supplementary Figure S44. Scatter plots of the cumulative variance explained by the genome-wide significant (p<5x10-8) independent (R2<0.01) single 
nucleotide polymorphisms (SNPs) for PC aa C42:1 (Biocrates) 
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Supplementary Figure S45.  Volcano plots representing the association between BMI and circulating Biocrates metabolites (triangle) and 
Metabolon metabolites (dots) from MR analyses.  




BMI: Body Mass Index 
* metabolite identity not yet confirmed by comparison with an authentic chemical standard 
 
 
Supplementary Figure S46. Scatter plots comparing the metabolite profile associated 
with kidney cancer from prospective observational analyses with the dental disease-
driven metabolite profile from MR analyses.  
Z score was calculated by dividing the effect estimate (log OR or beta) by the standard errors. 
Metabolites that are labelled have a p value below the threshold (p<0.05/Effective number of 
tests (ENT)) in the pooled analyses and are nominally significant in at least 2 cohorts separately. 
Metabolites measured by the Biocrates platform that are below the p value threshold are 
represented by triangles, those measured by the Metabolon platform that are below the p value 
threshold are represented by dots and those that are measured by either the Biocrates or the 
Metabolon platform that are above the p value threshold are represented by an x. 
 
MR: Mendelian Randomization; OR: Odds Ratio; SE: Standard Error. 
* metabolite identity not yet confirmed by comparison with an authentic chemical standard 
On the y-axis, the OR and SE were derived from the logistic regression analyses conditioned on case set estimating the 
associations between circulating metabolites and kidney cancer risk in five prospective cohorts.  
On the x-axis, the beta and SE were derived from the mendelian randomization analyses evaluating the effect of BMI on 
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Overview of the cohorts included in the study population 
 
European Prospective Investigation into Cancer and Nutrition (EPIC) 
The European Prospective Investigation into Cancer and Nutrition (EPIC) is an ongoing 
multicenter prospective cohort study designed primarily to investigate the relationship 
between nutrition and cancer. The recruitment and baseline assessment of the EPIC cohort 
are described in detail elsewhere[1,2]. Between 1992 and 2000, 521,330 individuals from 10 
European countries. In this project we included participants from France, Germany, Greece, 
Italy, the Netherlands, Norway, Spain and the United Kingdom were recruited. Participants 
completed self-administered questionnaires on their diet, lifestyle and medical history. 
Height and weight of individuals were measured using standard protocols.  Of the 521,330 
individuals, 385,747 individuals provided a blood sample. Blood fractions were aliquoted 
into 0.5mL straws, which were heat sealed and stored in liquid nitrogen tanks at -196oC. All 
participants gave written informed consent. The study was approved by the ethics 
committee at the International Agency for Research on Cancer (Lyon, France) and the local 
ethics committee of the study centres.  
Incident cancer cases were identified via linkage to population-based cancer registries (in 
Italy (except Naples), the Netherlands, Norway, Spain, and the United Kingdom) or by active 
follow-up (in France, Germany, Greece, and Naples), which involved a combination of 
methods, including review of health insurance records and cancer and pathology registries, 
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up from study entry until cancer diagnosis (except nonmelanoma skin cancer), death, 
emigration, or the end of follow-up.  
We identified 635 eligible kidney cancer cases defined as participants who were diagnosed 
with Kidney cancer (with International Classification of Diseases for Oncology, Second 
Edition, code C64 and C65), excluding prevalent cases and cases with a history of another 
cancer (except nonmelanoma skin cancer).  For each case, 1 control was chosen randomly 
from risk sets consisting of all cohort members who were alive and free of cancer (except 
nonmelanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were 
country, sex, date of blood collection (±1 month, relaxed to ±5 months for sets without 
available controls), and date of birth (±1 year relaxed to ±5 years for sets without available 
controls). Written informed consent was obtained from all participants. In total, 635 
matched case-controls pairs were included in our study. 
 
Northern Sweden Health and Disease study (NSHDS) 
The Northern Sweden Health and Disease Study (NSHDS) includes several prospective 
cohorts[3]. The current study included study participants from the Västerbotten 
Intervention Project (VIP) , which is a sub-cohort within NSHDS. The ongoing VIP prospective 
cohort is an intervention study aimed at health promotion of the general population of the 
Västerbotten County in Sweden. In 1985, when VIP was started, all residents in the 
Västerbotten County were invited to participate by attending a health check-up at 40, 50 
and 60 years of age. Participants were asked to complete a self-administered questionnaire 
that inquired about various population characteristics such as education, smoking habits, 
physical activity, diet, height and weight. Fasting blood samples were collected from 
participants during a medical examination. Blood specimens were collected and processed 
by centrifugation and separation and frozen at -80oC within 1 hr of collection. Plasma 
samples were stored in the Medical Biobank (Umea, Sweden).  
Newly identified cancer cases were identified through linkage with the Swedish Cancer 
Registry and the local Northern Sweden Cancer Registry. Eligible controls were selected 
among those who were alive and cancer-free at the time of the case’s diagnosis and 
matched on birthdate (within 2.5 years), sex, blood draw date (within the same year), and 
fasting status. This study was approved by the Ethics Committee of the Faculty of medicine 




participants. In total, 163 incident kidney cancer cases and 163 individually matched 
controls were included in our study. 
 
The Trøndelag Health Study (HUNT) 
The Trondelag Health Study (HUNT) includes repeated surveys of a large population-based 
cohort in Norway[4].  Data from 570 individuals aged 20 years and older from HUNT2 (1995 
to 1997, n=416) and HUNT3 (2006 to 2008, n=154) were used in this study. Individuals who 
participated in both HUNT2 and HUNT3 were included as part of HUNT3. Blood samples 
were collected at the health examination stations and stored in the HUNT biobank at -70oC 
for later use. The self-administered questionnaires used in HUNT included medical history, 
smoking, alcohol consumption. Weight (kg) and height (cm) were measured in a 
standardized manner in HUNT2 and HUNT3.  Body mass index (BMI) was calculated as 
weight (kg) divided by height (m) squared. Blood samples were collected at the time of 
participation as described in in the Cohort paper[4] and earlier in this section. The study was 
approved by the Regional Committee for Ethics in Medical Research, the National 
Directorate of Health, and by the Norwegian Data Inspectorate.   
The mandatory reporting of cancer by physicians and hospitals to the Cancer Registry of 
Norway (www.krefregisteret.no) provides information on incident cases of kidney cancer 
that occurred during follow-up. Incident kidney cancer cases were identified using ICD10 
codes (C 64) and we acquired information on date of first diagnosis of participants from the 
Cancer Registry of Norway. All participants with previous cancer diagnosis were excluded. 
One randomly selected control, matched by sex, age ±2 years, date of blood collection (± 2 
months) and time since last meal when blood sample was collected (fasting status). Controls 
were alive and did not have a cancer diagnosis at the diagnosis time of their index case. 
Written informed consent was obtained from all participants. In total, 254 matched case-
controls pairs were included in our study. 
 
The Melbourne Collaborative Cohort Study (MCCS)  
The Melbourne Collaborative Cohort Study (MCCS) is a prospective study of 41,513 healthy 
adult volunteers (24,469 women) aged between 27 and 76 years (99.3% aged 40-69) when 
recruited between 1990 and 1994[5,6]. At baseline, demographic characteristics and 




smoking and alcohol consumption) while height, weight, and waist and hip circumferences 
were measured. Peripheral blood was drawn at recruitment (1990-1994) or at subsequent 
follow-up (2003-2007). The study was approved by Cancer Council Victoria’s Human 
Research Ethics Committee and performed in accordance with the institution’s ethical 
guidelines. 
Cases of kidney cancer were identified by record linkage with the Victorian Cancer Registry 
that receives mandatory notification of all new cancer cases in Victoria, Australia. Diagnostic 
pathology reports were reviewed and classified according to the International Classification 
of Disease (ICD-0-3 WHO classification). Subjects with any history of kidney cancer before 
blood collection were excluded. Controls were individually matched to cases by age, sex and 
country of birth. Study participants provided informed consent in accordance with the 
Declaration of Helsinki. In total, 140 incident kidney cancer cases and 140 individually 
matched controls were included in our study. 
 
University of Tartu - Estonian Biobank (Estonian BB) 
The Estonian Genome Center, The University of Tartu (EGCUT), cohort is a population 
biobank containing 5% of the Estonian adult population. Detailed description of the 
Estonian cohort was described previously[7]. The age, sex and geographical distribution of 
the 152,000 participants closely reflect those of the Estonian adult population. EGCUT can 
link its own database with the national electronic databases (eight total) to constantly 
update the phenotype information of the participants. Every entry in the biobank consists 
of: (i) biological samples, (ii) answers to the questions of a computer-assisted personal 
interview conducted at the doctor’s office (including questions about smoking and alcohol 
consumption), (iii) objective measurements performed at the doctor’s office (including 
weight, height, waist and hip circumferences and blood pressure), (iv) electronic health data 
from various databases, (v) genotype data from array genotyping, exome sequencing, or 
whole-genome sequencing, and (vi) biomedical data obtained by performing various assays 
on the material collected. Written informed consent was obtained from all participants for 
the baseline and follow-up investigations. 
Kidney cancer cases were identified through national cancer registries and through 
independent review of medical records. For diagnosis of kidney cancer, we used the ICD-10 




collection, sex and time of blood collection. Controls were individuals who were alive and 
without a diagnosis of kidney cancer at time of the case’s diagnosis date. In total, 115 
matched case-controls pairs were included in our study 
 
Metabolite data acquisition 
Biocrates 
The targeted metabolomics approach was based on LC-ESI-MS/MS and FIA-ESI-MS/MS 
measurements by AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria).  
The assay allows simultaneous quantification of 188 metabolites out of 10 µL plasma or 
serum, and includes free carnitine, 39 acylcarnitines (Cx:y), 21 amino acids (19 
proteinogenic + citrulline + ornithine), 21 biogenic amines, hexoses (sum of hexoses – about 
90-95 % glucose), 90 glycerophospholipids (14 lysophosphatidylcholines (lysoPC) and 76 
phosphatidylcholines (PC)), and 15 sphingolipids (SMx:y). The abbreviations Cx:y are used to 
describe the total number of carbons and double bonds of all chains, respectively (for more 
details see 1). The method of AbsoluteIDQ p180 Kit has been proven to be in conformance 
with the EMEA-Guideline "Guideline on bioanalytical method validation (July 21st 2011”) 
[8], which implies proof of reproducibility within a given error range. The long-time stability 
of plasma metabolites during storage at -80 °C and the performance of the targeted-
metabolomics platform using the AbsoluteIDQ p180 Kit have been evaluated in [9]. 
 
In the IARC laboratory, a liquid chromatography-tandem mass spectrometry system (Agilent 
UHPLC-1290/Sciex QTRAP5500 (AB Sciex, Framingham, MA, USA) was used to measure 
metabolites levels. For the LC-part, compound identification and quantification were based 
on scheduled multiple reaction monitoring measurements (sMRM). Sample preparation and 
LC-MS/MS measurements were performed as described in the manufacturer in manual UM-
P180-Sciex-13.  Analytical specifications for the limit of detection (LOD) and evaluated 
quantification ranges, further LOD for semiquantitative measurements, identities of 
quantitative and semiquantitative metabolites, specificity, potential interferences, linearity, 
precision and accuracy, reproducibility and stability were described in Biocrates manual AS-




saline solution). The lower and upper limits of quantification were determined 
experimentally by Biocrates. 
In the Helmholtz Zentrum München, an API4000 mass spectrometer (Sciex Deutschland 
GmbH, Darmstadt, Germany) was used to measure metabolites levels. The assay procedures 
of the AbsoluteIDQ p180 Kit as well as the metabolite nomenclature have been described in 
detail previously[10].  Sample handling was performed by a Hamilton Microlab STARTM 
robot (Hamilton Bonaduz AG, Bonaduz, Switzerland) and a Ultravap nitrogen evaporator 
(Porvair Sciences, Leatherhead, U.K.), beside standard laboratory equipment. Mass 
spectrometric analyses were done on an API 4000 triple quadrupole system (Sciex 
Deutschland GmbH, Darmstadt, Germany) equipped with a 1200 Series HPLC (Agilent 
Technologies Deutschland GmbH, Böblingen, Germany) and a HTC PAL auto sampler (CTC 
Analytics, Zwingen, Switzerland) controlled by the software Analyst 1.6.2. Data evaluation 
for quantification of metabolite concentrations and quality assessment was performed with 
the software MultiQuant 3.0.1 (Sciex) and the MetIDQ™ software package, which is an 
integral part of the AbsoluteIDQ Kit. Metabolite concentrations were calculated using 
internal standards and reported in µM.  
 
Metabolon 
All samples were maintained at -80oC until processed. Samples were prepared with use of 
an automated MicroLab STAR system (Hamilton Company, Reno, NV, USA). For quality 
control (QC), a pooled sample from all experimental samples was used throughout the 
experiment, and a mixture of Metabolon QC standards were spiked into all experimental 
samples to monitor instrument performance and chromatographic alignment. Samples were 
randomised prior to experimentation. Experiments were conducted on Waters Acuity ultra-
performance liquid chromatography (UPLC) systems (Waters Corporation, Milford, MA, 
USA) using Thermo Scientific Q- Exactive high resolution/accurate mass spectrometer 
interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyser 
(Thermo Fisher Scientific, MA, USA). The analysis platform used four methods for Ultrahigh 
Performance Liquid Chromatography- Tandem Mass Spectroscopy (UPLC-MS/MS) including 
a) positive ion mode electrospray ionisation (ESI), b) positive ion mode optimised for 
hydrophobic compounds, c) negative ion mode ESI and d) negative ionisation following 




between methods and covered 70- 1000m/z.:  Raw data was extracted, peak-identified and 
QC processed using Metabolon’s hardware and software.  Metabolites were identified by 
comparison to the in-house Metabolon standard library using retention time, mass (m/z), 
adducts and MS/MS spectra. As experiments were conducted over multiple consecutive 
days, a data normalization step was performed to correct variation resulting from 
instrument inter-day tuning differences.  
The cases and their matched controls were assayed within the same batches in order to avoid 
any effect of batch differences on the risk estimates. 
Instrument variability was determined by calculating the median relative standard deviation 
(RSD) for the internal standards that were added to each sample prior to injection into the 
mass spectrometers. Overall process variability was determined by calculating the median 
RSD for all endogenous metabolites (i.e., non-instrument standards) present in the MTRX5 
technical replicates (a large pool of human plasma maintained by Metabolon that has been 
characterized extensively).   
Values for instrument and process variability meet Metabolon’s acceptance criteria: median 
RSD for internal standards were 5% and 4% for EPIC and NSHDS samples, respectively; 
median RSD for endogenous biochemicals were 11% for both EPIC and NSHDS. 
 
Data sources for Mendelian randomization analyses 
BMI GWAS 
Summary-level GWAS data for BMI was obtained from a 2018 meta-analysis of GWASs of 
BMI [11] (downloaded from: 
https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_f
iles#2018_GIANT_and_UK_BioBank_Meta-analysis). This analysis was a fixed-effects meta-
analysis combining results from a GWAS of BMI performed among 456,426 participants 
from the UK Biobank (adjusted for age, sex, recruitment center, genotyping batch and 10 
genetic principal components) and results from a BMI GWAS published by the GIANT 
(Genetic Investigation of Anthropometric Traits)[12] consortium, which included 253,288 
participants from 79 studies (adjusted for age, sex, and study specific covariates). For UK 
Biobank, BMI (weight in kg per height in metres squared) was measured during the initial 
assessment centre visit whereas for the BMI GWAS conducted by the GIANT consortium, 






Summary-level GWAS data for 174 Biocrates metabolites [13] and 913 Metabolon 
metabolites were used. The metabolite GWAS data used in the MR analyses, are available 
via www.omicscience.org for all Biocrates and a subset of Metabolon metabolites. 
Metabolite associations for the BMI-associated and dental disease-associated SNPs used in 
the Mendelian randomization analyses are available to download from:[**data.bris.url to be 
inserted on acceptance of manuscript**].  
 
Biocrates: 
The GWAS meta-analysis for the 174 Biocrates metabolites was a fixed-effects meta-analysis 
combining results from the Fenland cohort [14] (maximum N= 9736, available at: 
https://omicscience.org/apps/crossplatform/) (metabolites profiled by the Biocrates p180 
kit and measured using mass spectrometry) with those from the EPIC-Norfolk [15] 
(maximum N=5841) and INTERVAL studies [16] (maximum N=40,818) (metabolites were 
profiled using mass spectrometry (Metabolon Discovery HD4 platform) and proton nuclear 
magnetic resonance (1H-NMR) spectroscopy). Ten of the 174 Biocrates metabolites were 
covered across all platforms, while 38 were available on the Biocrates and Metabolon 
platforms and 126 were unique to Biocrates. An overall z-score meta-analysis was also 
conducted by further integrating publicly available summary statistics from GWAS of the 
same metabolites measured using mass spectrometry (with Biocrates or Metabolon 
platforms[17,18]) or 1H-NMR spectroscopy [18] (N=ranged from 8,569 to 86,507 for 
different metabolites, available at: https://omicscience.org/apps/crossplatform/). 
 
Genotyping in Fenland was performed using Affymetrix SNP5.0 and Affymetrix Axiom and 
genotype imputation was performed using 1000 Genomes Phase 1v3 or phase 3 reference 
panels. In EPIC-Norfolk, genotype imputation was performed using 1000 Genomes Phase 3 
reference panels. Genotyping in INTERVAL was performed using Affymetrix Axiom and 
imputation was performed using the 1000 Genomes Phase 3 (May 2013)-UK10K reference 
imputation panel. For Fenland and EPIC-Norfolk, GWAS analyses were carried out using 
BOLT-LMM and SNPTEST adjusting for age, sex and study-specific covariates in mixed linear 




gender, metabolon batch, INTERVAL centre, plate number, appointment month, the lag 
time between the blood donation appointment and sample processing, and the first 5 
ancestry principal components.  
 
For the pleiotropy analyses, SNPs associated with metabolites at p<4.9x10-10 (conventional 
threshold of genome-wide significance corrected for 102 tests which corresponded to the 
number of principal components that explained 95% of the variance of the 174 metabolites 
in the Fenland cohort) were identified from the overall z-score meta-analysis. The estimated 
effect sizes for each of the metabolite-associated SNPs were then obtained from the three-
cohort meta-analysis (Fenland and, when available, EPIC-Norfolk and/or INTERVAL) and only 
metabolite-associated SNPs with a p<5x10-08 in the three-cohort meta-analysis was included 
in the pleiotropy analyses. For the MR analyses, the metabolite associations for the BMI-
associated SNPs or dental disease-associated SNPs were obtained from the three-cohort 
meta-analysis.   
 
Metabolon: 
A GWAS of metabolon metabolite levels was performed using samples from the EPIC-
Norfolk [15] and INTERVAL studies [19]. 14,296 participants were included in a discovery set 
(5,841 from EPIC-Norfolk; 8,455 from INTERVAL) and 5,698 from EPIC-Norfolk in a validation 
set. Metabolites were measured using the Metabolon DiscoveryHD4 platform (Metabolon, 
Inc., Durham, USA), from plasma samples collected at baseline. A total of 913 metabolites 
measured in at least 100 participants in each study were taken forward for GWAS analysis. 
Metabolite measures were median normalised for run day, log transformed, winsorised to 5 
standard deviations, before being regressed against age, sex and study specific variables 
using linear regression. Residuals from this regression were standardised (mean 0, standard 
deviation 1) and used for further analysis. Genotyping was performed using the Affymetrix 
Axiom UK Biobank genotyping array. In INTERVAL, genotype imputation was performed 
using the combined UK10K+1000 Genomes Phase 3 reference panel. In EPIC-Norfolk, 
imputation was performed using the Haplotype Reference Consortium reference panel, with 





Association analyses were performed using BOLT-LMM [20] or SNPTEST [21,22] separately 
in each study and combined using inverse variance weighted fixed effect meta-analysis 
methods implemented in METAL [23]. Genome-wide significant (p < 5 x 10-8) lead regional 
associations that were directionally consistent and significant at p < 0.01 in both studies 
were considered validated if they were significant at p < 5.48 x 10-11 (p < 5 x 10-8 Bonferroni 
corrected for 913 metabolites) and directionally consistent in a meta-analysis including the 
independent validation samples, as described above. To identify independent associations, 
exact conditional analyses were then performed using forward stepwise regression with a 
significance threshold of p < 1.25 x 10-8. For the current study, unconditional effect 
estimates for both primary and conditionally independent associations were used. In 
analyses to assess pleiotropy of potential instruments, we obtained the effect estimates 
from the unconditional analysis and all SNPs used had a p<5 x10-08  in the unconditional 
analysis.  
 
Dental disease GWAS 
Summary-level data for dental disease was obtained from a 2019 meta-analysis of GWASs of 
dental disease (DMFS (Decayed, Missing and Filled tooth Surfaces); N=26,792 from 9 
studies) and dentures (ncase= 77,714 and ncontrols = 383,317) [24] (downloaded from: 
https://data.bris.ac.uk/data/dataset/2j2rqgzedxlq02oqbb4vmycnc2). This analysis was a 
fixed effects meta-analysis combining results from a GWAS of dental disease performed in 
the UK Biobank (adjusted for age, age-squared, sex, genotyping batch) and a GWAS of 
dental disease conducted by GLIDE (Gene-Lifestyle Interactions in Dental Endpoints) 
(adjusted for age, age-squared, genetic principal components and other study-specific 
covariates). Dental disease. Self-reported measures of oral health were characterised in UK 
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